Tumor Biology

, Volume 36, Issue 11, pp 8973–8984 | Cite as

The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks

Research Article

Abstract

Fisetin and hesperetin, flavonoids from various plants, have several pharmaceutical activities including antioxidative, anti-inflammatory, and anticancer effects. However, studies elucidating the role and the mechanism(s) of action of fisetin and hesperetin in acute promyelocytic leukemia are absent. In this study, we investigated the mechanism of the antiproliferative and apoptotic actions exerted by fisetin and hesperetin on human HL60 acute promyelocytic leukemia cells. The viability of HL60 cells was evaluated using the MTT assay, apoptosis by annexin V/propidium iodide (PI) staining and cell cycle distribution using flow cytometry, and changes in caspase-3 enzyme activity and mitochondrial transmembrane potential. Moreover, we performed whole-genome microarray gene expression analysis to reveal genes affected by fisetin and hesperetin that can be important for developing of future targeted therapy. Based on data obtained from microarray analysis, we also described biological networks modulated after fisetin and hesperetin treatment by KEGG and IPA analysis. Fisetin and hesperetin treatment showed a concentration- and time-dependent inhibition of proliferation and induced G2/M arrest for both agents and G0/G1 arrest for hesperetin at only the highest concentrations. There was a disruption of mitochondrial membrane potential together with increased caspase-3 activity. Furthermore, fisetin- and hesperetin-triggered apoptosis was confirmed by annexin V/PI analysis. The microarray gene profiling analysis revealed some important biological pathways including mitogen-activated protein kinases (MAPK) and inhibitor of DNA binding (ID) signaling pathways altered by fisetin and hesperetin treatment as well as gave a list of genes modulated ≥2-fold involved in cell proliferation, cell division, and apoptosis. Altogether, data suggested that fisetin and hesperetin have anticancer properties and deserve further investigation.

Keywords

Fisetin Hesperetin Apoptosis Acute promyelocytic leukemia Gene profiling 

Notes

Acknowledgements

Declared none

Conflicts of interest

None

References

  1. 1.
    Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014;27:3–9.CrossRefPubMedGoogle Scholar
  2. 2.
    de Thé H, Le Bras M, Lallemand-Breitenbach V. Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol. 2012;198:11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mi J. Current treatment strategy of acute promyelocytic leukemia. Front Med. 2011;5:341–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of cancer. Biochem Pharmacol. 2008;76:1333–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol. 2013;45:2821–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19:151–62.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett. 2008;265:167–76.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lu X, Jung J, Cho HJ, Lim DY, Lee HS, Chun HS, et al. Fisetin Inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr. 2005;135:122884–90.Google Scholar
  9. 9.
    Murtaza I, Adhami VM, Hafeez BB, Saleem M, Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3 mediated inhibition of NF-κB. Int J Cancer. 2009;2:2465–73.CrossRefGoogle Scholar
  10. 10.
    Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 2012;84:1277–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Liao YC, Shih YW, Chao CH, Lee XY, Chiang TA. Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J Agric Food Chem. 2009;57:8933–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Lim do Y, Park JH. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol. 2009;296(5):G1060–8.Google Scholar
  13. 13.
    Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. 2008;56:6185–205.CrossRefPubMedGoogle Scholar
  14. 14.
    Nielsen IL, Chee WS, Poulsen L, Offord-Cavin E, Rasmussen SE, et al. Frederiksen, bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr. 2006;136:404–8.PubMedGoogle Scholar
  15. 15.
    Chen YC, Shen SC, Lin HY. Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem Pharmacol. 2003;66:1139–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Sivagami G, Vinothkumar R, Bernini R, Preethy CP, Riyasdeen A, Akbarsha MA, et al. Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT-29 human colon adenocarcinoma cell line—a comparative study. Food Chem Toxicol. 2012;50:660–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Choi EJ. Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21. Nutr Cancer. 2007;59:115–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Khan N, Afaq F, Syed DN, Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis. 2008;29:1049–56.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kang KA, Piao MJ, Hyun JW. Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway. In Vitro Cell Dev Biol Anim. 2015;51:300–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Jang KY, Jeong SJ, Kim SH, Jung JH, Kim JH, Koh W, et al. Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin induced apoptosis in multiple myeloma U266 cells. Cancer Lett. 2012;319:197–202.CrossRefPubMedGoogle Scholar
  22. 22.
    Palit S, Kar S, Sharma G, Das PK. Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ROS and activation of ASK1/JNK pathway. J Cell Physiol. 2015;230(8):1729–39.Google Scholar
  23. 23.
    Alshatwi AA, Ramesh E, Periasamy VS, Subash-Babu P. The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. Fundam Clin Pharmacol. 2013;27:581–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Peyressatre M, Prével C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers (Basel). 2015;7(1):179–237.CrossRefGoogle Scholar
  25. 25.
    Pal HC, Sharma S, Elmets CA, Athar M, Afaq F. Fisetin inhibits growth, induces G2/M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation. Exp Dermatol. 2013;22:470–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9:68–76.CrossRefPubMedGoogle Scholar
  27. 27.
    Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, et al. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2011;108:84–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Escrich E, Moral R, Garcia G, Costa I, Sanchez JA, Solanas M. Identification of novel differentially expressed genes by the effect of a high-fat n-6 diet in experimental breast cancer. Mol Carcinog. 2004;40:73–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L, et al. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer. 2013;13:468. doi: 10.1186/1471-2407-13-468.
  30. 30.
    Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc’h N, et al. Beneficial role of overexpression of TFPI2 on tumour progression in human small cell lung cancer. FEBS Open Bio. 2013;3:291–301.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci. 2000;113:3897–905.PubMedGoogle Scholar
  32. 32.
    Chen D, Forootan SS, Gosney JR, Forootan FS, Ke Y. Increased expression of ID1 and ID3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer. Genes Cancer. 2014;5:212–25.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kim S, Kim SY, Ku HJ, Jeon YH, Lee HW, Lee J, et al. Suppression of tumorigenesis in mitochondrial NADP(+)-dependent isocitrate dehydrogenase knock-out mice. Biochim Biophys Acta. 1842;2014:135–43.Google Scholar
  34. 34.
    Bota DA, Ngo JK, Davies KJ. Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. Free Radic Biol Med. 2005;38:665–77.CrossRefPubMedGoogle Scholar
  35. 35.
    Anisowicz A, Sotiropoulou G, Sager R. Re-expression of SPR1 in breast cancer cells by phorbol 12-myristate 13-acetate (PMA) or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter. Mol Med. 1999;5:526–41.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Lu DD, Chen YC, Zhang XR, Cao XR, Jiang HY, Yao L. The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale J Biol Med. 2003;76:55–62.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Yan DW, Fan JW, Yu ZH, Li MX, Wen YG, Li DW, et al. Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue. Biochim Biophys Acta. 2012;1822(6):918–26.CrossRefPubMedGoogle Scholar
  38. 38.
    Meng Q, Zheng M, Liu H, Song C, Zhang W, Yan J, et al. SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem. 2013;373:201–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, et al. Neuromedin U: a Myb regulated autocrine growth factor for human myeloid leukemias. Blood. 2004;104:1833–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Guo L, Chen S, Jiang H, Huang J, Jin W, Yao S. The expression of S100P increases and promotes cellular proliferation by increasing nuclear translocation of β-catenin in endometrial cancer. Int J Clin Exp Pathol. 2014;7(5):2102–12.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Wu TS, Tan CT, Chang CC, Lin BR, Lai WT, Chen ST, et al. B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway. Oncogene. 2015;34(10):1207–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken). 2010;67:214–23.CrossRefGoogle Scholar
  43. 43.
    Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19:1–11.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, et al. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014;5:8503–14.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Molecular Biology and Geneticsİzmir Institute of TechnologyUrlaTurkey
  2. 2.Faculty of Life and Natural SciencesAbdullah Gul UniversityKayseriTurkey

Personalised recommendations